CSL Limited (CSLLY)
75.56
-0.73 (-0.96%)
At close: Apr 21, 2025, 3:59 PM
-0.96% (1D)
| Bid | 75.38 |
| Market Cap | 146.35B |
| Revenue (ttm) | 14.98B |
| Net Income (ttm) | 2.76B |
| EPS (ttm) | 2.72 |
| PE Ratio (ttm) | 27.78 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 75.75 |
| Volume | 15,886 |
| Avg. Volume (20D) | 99,304 |
| Open | 76.45 |
| Previous Close | 76.29 |
| Day's Range | 75.27 - 76.25 |
| 52-Week Range | 70.22 - 109.00 |
| Beta | 0.35 |
About CSLLY
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioede...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 29, 2009
Employees 32,698
Stock Exchange PNK
Ticker Symbol CSLLY
Website https://www.csl.com.au
